Stocks ended flat Tuesday as investors took a breather after Monday's blockbuster rally.

Federal regulators added stronger warnings to a group of best-selling drugs used to treat arthritis and other inflammatory diseases, saying they can increase the risk of cancer in children and adolescents.

Stocks struggled to stay in positive territory for any length of time Tuesday as profit-taking after Monday's blockbuster rally overshadowed a fifth-straight rise in pending-home sales.

Stocks bounced back from a lower open Tuesday after a surprisingly sharp jump in pending-home sales.

Futures suggested stock would retreat Tuesday after a milestone session on Monday that sent the S&P over 1,000 for the first time since November.

Stocks ended slightly lower Tuesday, though the Nasdaq eked out a gain. And Citigroup shares soared.

Stocks skidded Tuesday after a report showed consumer confidence is waning amid worries about the job market. It was a struggle all morning as investors juggled another batch of disappointing earnings results against an encouraging report on the housing market.

Stock futures drifted slightly lower ahead of the open Tuesday as investors waited for the next batch of earnings and key economic data.

Stocks eked out a gain Monday as banks got a boost from a jump in new-home sales. Stocks had struggled for much of the day as investors worried about a a record $200 billion in Treasury auctions this week and lowered outlooks from Honeywell and Aetna cast a shadow over the market.

The Dow poked into positive territory Monday afternoon, led by Bank of America, as a jump in new-home sales buoyed bank stocks. Still, the blue-chip index struggled to stay above water as worries about a record $200 billion in Treasury auctions this week and lowered outlooks from Honeywell and Aetna cast a shadow over the market.

Stocks got a quick pop Monday after a sharp jump in new home sales, but quickly resumed their decline as lowered outlooks from Honeywell and Aetna cast a shadow over the market.

Stock index futures edged higher ahead of the open Monday as investors look to see if the summer rally will keep pushing the major indexes higher.

A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?

A late upturn pushed stocks higher Wednesday as investors rotated into defensive stocks like pharmaceuticals and Alcoa advanced ahead of earnings.

Stocks turned lower Wednesday as investors got defensive ahead of earnings season, rotating into pharmaceuticals and out of techs.